What are the limitations of the ipss r?

While the ipss r is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the ipss r to ensure safe bedside use and optimal diagnostic accuracy.

How does the ipss r compare to other Hematology scores?

The ipss r is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the ipss r free to use?

Yes. OpiCalc provides the ipss r completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

935 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

IPSS-R (Revised IPSS for MDS)

IPSS-R: The gold standard for de novo MDS prognostic stratification. Weighted for Cytogenetics, Blasts, and Peripheral Cytopenias.

Cytogenetics

Marrow Blasts (%)

Haemoglobin (g/dL)

Platelets (× 10⁹/L)

ANC (× 10⁹/L)

Total IPSS-R Score

0

Risk Category

Very Low

Median Survival: 8.8 yr

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Initial risk stratification of patients with newly diagnosed Myelodysplastic Syndromes (MDS).

Predicting the risk of transformation to Acute Myeloid Leukemia (AML) and overall survival.

Guiding treatment decisions, such as the timing of stem cell transplantation or therapeutic intervention (e.g., HMAs).

Patient Population

Adult patients with de novo MDS. While validated in older cohorts, its values remain discriminative across age groups.

When Not to Rely on This Score Alone

Secondary or therapy-related MDS (t-MDS) — these patients typically have worse outcomes than predicted by IPSS-R.

MDS with excess blasts > 30% — this is classified as AML in modern systems (WHO 2022 / ICC).

Patients with significant comorbidities — patient fitness should be assessed alongside biological risk.

Section 2

Formula & Logic

Scoring variables

Factor	Score Points
Cytogenetics	Very Good (0), Good (1), Intermed (2), Poor (3), V. Poor (4)
Marrow Blast %	≤ 2 (0), > 2–5 (1), 5–10 (2), > 10 (3)
Haemoglobin (g/dL)	≥ 10 (0), 8–10 (1), < 8 (1.5)
Platelets (× 10⁹/L)	≥ 100 (0), 50–100 (0.5), < 50 (1)
ANC (× 10⁹/L)	≥ 0.8 (0), < 0.8 (0.5)

Risk Groups (Total Score)

Score	Risk Group	Median Survival (yr)	AML Transformation
≤ 1.5	Very Low	8.8	Never (median)
> 1.5 – 3	Low	5.3	10.8
> 3 – 4.5	Intermediate	3.0	3.2
> 4.5 – 6	High	1.6	1.4
> 6	Very High	0.8	0.73

Section 3

Pearls/Pitfalls

Cytogenetic Priority

Cytogenetics remains the most powerful predictor in the IPSS-R. A patient with a "Very Poor" cytogenetic profile (e.g., > 3 abnormalities) is assigned to the High/Very High risk group regardless of blast count or blood counts.

IPSS-M Update

The IPSS-R has been the gold standard for a decade. However, the new **IPSS-M (Molecular)** integrates 16-gene somatic mutation profiles and is increasingly used in academic centers.

Section 4

Evidence Appraisal

Primary Score

Revised international prognostic scoring system for myelodysplastic syndromes.

Greenberg PL et al. • Blood. 2012;120(12):2454-65. n=7,012 patients.

View Source

Section 5

Literature

Development

The Revised IPSS (IPSS-R) was developed by the International Working Group for Prognosis in MDS (IWG-PM) to improve upon the original 1997 IPSS by weighting factors more granularly and incorporating five cytogenetic risk groups instead of three.

Last Comprehensive Review: 2026

Related Hematology Tools

YEARS Algorithm

Age-adjusted D-dimer Threshold

sPESI

HEP Score

HERDOO2 Rule

Vienna Prediction Model

Padua RAM

Antiphospholipid Syndrome Classification

GAPSS

Thrombophilia Screening Eligibility Algorithm

Have feedback about this calculator?Let us know.